Adverse effect signal1 papers
The study reported that 70% ethanol ashwagandha root extracts modulated CYP3A4 enzyme expression and activity in primary human hepatocytes, highlighting potential risks for co-administration with prescribed drugs.Cell studies · Study type not identifiedAdverse effect signal1 papers
Preliminary studies observed dose- and time-dependent cytotoxic effects on hepatocyte viability at high concentrations of 70% ethanol ashwagandha leaf extracts.Cell studies · Study type not identifiedGastrointestinal issues1 papers
Some studies included in the review report gastrointestinal issues associated with Ashwagandha supplementation.Human studies · Systematic reviewAdverse effect signal1 papers
The review states that potential interactions with medications are reported, necessitating caution and consultation with healthcare providers.Human studies · Study type not identifiedTreatment-emergent adverse events (nausea, abdominal pain, drowsiness)1 papers
Seven participants in the Ashwagandha group reported mild adverse events including nausea, abdominal pain, and drowsiness, which resolved without intervention.Human studies · Randomized controlled trialGastrointestinal-related adverse events1 papers
Gastrointestinal-related adverse events were reported in 53 participants in the Withania somnifera arm, described as excellent tolerability overall.Human studies · Randomized controlled trial